第三十卷第二� �.pdf

The bulletin discusses two cases:

1. A case of hypofibrinogenemia (low fibrinogen levels) in an 88-year-old patient treated with tigecycline for pneumonia. The patient's fibrinogen levels decreased from 483 mg/dL to 88.5 mg/dL after five days of treatment, but returned to normal after the drug was discontinued.

2. A case of chronic migraine in a 40-year-old woman who was treated with botulinum toxin type A (BOTOX) injections. The patient had been experiencing frequent and severe headaches, and had developed medication-overuse headache due to excessive use of painkillers. The BOTOX injections were effective in reducing the frequency and severity of her headaches.

The bulletin also includes a discussion on the use of tigecycline and its potential side effects, including hypofibrinogenemia and coagulopathy. It also provides information on the use of botulinum toxin type A for the prevention of chronic migraine, including the recommended dosage and potential side effects.

Additionally, the bulletin includes a section on medication safety alerts, which highlights two recent warnings from the US FDA:

1. A warning about the potential increased risk of cancer associated with the use of lorcaserin (Belviq, Belviq XR) for weight management.

2. A warning about the risk of severe gastrointestinal disorders, including intestinal obstruction and ischemia, associated with the use of clozapine (Clozaril) for the treatment of schizophrenia.